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Colorectal cancer (CRC) is the third leading cause of cancer
deaths, with an estimated 430 000 deaths per year world-wide
(Pisani et al, 1999). A multidisciplinary approach, which includes
surgery, chemotherapy and radiotherapy, is taken when treating
carcinoma of the large bowel. However, approximately half of the
patients who undergo potentially curative surgery for CRC will
eventually die from recurrent disease (Boring et al, 1993). Disease
stage at presentation is the major predictor of outcome, with early
stage tumours (Dukes’ A & B) having a much better survival than
late stage disease (Dukes’ C & D). However, there is considerable
variability in survival rates within these classifications (Moertel
et al, 1995). Efforts to complement the pathologic staging system
with markers of prognosis in CRC are still at a relatively early
stage of development and most studies are focused on the correla-
tion of protein expression with eventual outcome (McLeod et al,
1999). This is of particular importance in locally advanced CRC
(Dukes’ C), where systemic chemotherapy is administered to most
patients even though it will improve survival for only 15% of
patients (Moertel et al, 1995). 
Over the last decade, a substantial amount of knowledge has
been accumulated using cytogenetics and molecular analyses to
elucidate the mechanisms behind CRC. The current understanding
of the genetic events responsible for the stepwise progression from
normal colonic epithelium to invasive carcinoma (Fearon and
Vogelstein, 1990) has been greatly aided by whole genomic
analysis of this tumour type by comparative genomic hybridiza-
tion (CGH) (Kallioniemi et al, 1992; Rooney et al, 1999). CGH
has identified specific chromosomal regions which are consis-
tently gained (e.g. 20q and 13q) or lost (e.g. 18q) at a high
frequency in CRC and has demonstrated an increase in the genetic
grade of a tumour (i.e. the overall number of genomic aberrations)
with disease progression (Reid et al, 1996; Al-Mulla et al, 1999).
What is less well defined is the influence of genomic aberrations
on patient survival. 
In this report, the specific genomic aberrations and overall
level of chromosomal stability, as identified by CGH, was
evaluated in Dukes’ C CRC and assessed for an influence on
survival. In addition the chromosomal aberrations identified in
the Dukes’ C tumours were compared with a panel of 8 CRC cell
lines to evaluate their usefulness as model systems for CRC
genomics. 
MATERIALS AND METHODS 
Chemicals 
DNA polymerase I, DNase I, Igepal CA-630 and dNTPs were
obtained from Sigma-Aldrich (Poole, Dorset, UK). SpectrumRed
dUTP and SpectrumGreen dUTP were purchased from Vysis
(Richmond, Surrey, UK). Human Cotl DNA, RPMI 1640 media,
fetal calf serum, glutamine, penicillin and streptomycin were from
GibcoBRL (Gaithersburg, MD, USA) and formamide from Fluka
(New-Ulm, Germany). The Nucleon II extraction kit used
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was from Scotlab (Coatbridge, UK), dextran sulphate was from
Pharmacia Biotech (Uppsala, Sweden), and DAPI/antifade
was purchased from Amersham Oncorappligene (Durham, UK).
All other reagents, chemicals and buffers were purchased from
BDH (Poole, Dorset, UK). 
Cell lines growth conditions 
All eight colorectal cell lines (R10, H630, RKO, HT29, DLD1,
CACO2, BE, LOVO) were cultured in RPMI 1640 or DMEM/F10
medium supplemented with 10% fetal bovine serum, 2mM L-
Glutamine and 100U penicillin/streptomycin in a 37˚C incubator
with 5% CO2. All cell lines were passaged once a week using
trypsin/EDTA and split 1:10, with a subsequent media change
every 3–4 days. The cell lines were maintained in standard media
and were not selected for any distinct cellular or molecular pheno-
type. 
Tumour samples 
Primary tumours were collected from 29 consecutive patients
undergoing surgery for Dukes’C CRC at Grampian University
Hospitals Trust. This included 13 men and 16 women, with a
median age at diagnosis of 67 years (range 45–86 years). The 29
tumours studied were from the proximal colon (n = 9), distal
colon (n = 16), and rectum (n = 4). The minimum clinical follow-
up was 22 months, with a median of 29 months. At the time of
resection, a consultant pathologist dissected out a sample of the
tumour which was then snap-frozen in liquid nitrogen and stored
at –80˚C. Cells were isolated from colorectal tumours as follows:
Snap-frozen pieces of tumour were removed from –80˚C storage
and placed in a –20˚C cryostat machine. For each tumour, 6
sections were cut: 1–5 µ m section and 5–20 µ m sections. The 5
µ m section was then stained with haematoxylin and used as a
guide to remove normal cells from the 20 µ m sections.
Microdissection was performed with a scalpel using a dissecting
light microscope with a 20X objective. Following this, all the
remaining cells (tumour cells) were scraped into a 1.5 ml
microfuge tube containing reagent A from a Nucleon II DNA
extraction kit (Coatbridge, UK). DNA extraction was performed
according to the manufacturer’s instructions. Only tumour speci-
mens with over 50% tumour cellularity were included for CGH
analysis. The concentration of tumour DNA was quantified using
a fluorimeter. 
Comparative Genomic Hybridization 
CGH was performed as previously described (Rooney et al, 1998).
As a negative control, 200 ng of healthy human DNA labelled
with SpectrumGreen was hybridized with 200 ng of the same
DNA labelled with SpectrumRed fluorochrome. In addition, to
confirm equal sensitivity of both fluorochromes for detection of
gain and loss, and to reduce the likelihood of false positives (Barth
et al, 2000), all experiments were repeated with reverse labelling
of DNA (i.e. tumour DNA was labelled with SpectrumRed dUTP
and the reference DNA with SpectrumGreen dUTP). DAPI
counterstain was used to karyotype all processed metaphase
spreads. For each competitive hybridization reaction at least 10
metaphase spreads were analyszed. Chromosomal regions were
interpreted as over-represented (gain) in the test DNA if a fluores-
cence ratio (FR) of green to red fluorescence of > 1.15 was
observed, while regions with a FR of < 0.85 were interpreted as
under-represented (loss). Any region with a FR > 1.5 indicated
high level amplification. Genetic grade was calculated as the sum
of the number of losses and gains found in the tumour. 
Statistical analysis 
Kaplan-Meier log-rank analysis was used to evaluate the influence
of both specific chromosomal aberrations and the overall genetic
grade of each tumour on patient survival. A probability value of
less than 0.05 was considered significant. Statistical analyses was
carried out using SPSS for Windows 95 version 9.0 (SPSS UK
Ltd, Woking, Surrey, UK). 
RESULTS 
A high level of variation was seen in both the number and type of
genetic aberrations detected in the 29 Dukes’ C colorectal tumours
and the 8 colorectal cell lines assessed by CGH (Tables 1 and 2).
Table 1 Chromosomal aberrations detected by CGH in 8 colo-rectal cancer cell lines 
Cell line No. of Gains No. of losses Total no. of aberrations CGH aberrations 
(+ = Gain, – = Loss and ++ = High level amplification) 
R10 9 6 15 +1q21, +2p16-pter, +5p, +9p, +10p, +11q13-qter, 
+13q, +15q22–25, +20q12–13.2, –1p, –3p14–3q13.1, 
–4q, –5q -7p22 & –18q 
H630 8 6 14 +2p13–23, +5p, +7p11.23, +9p21–22, +10p12-pter, 
++13q, +18p, +20, –1p22.2–31.1, –4q, –5q15–31, 
–9q33-qter, –10q25 & –18q12.3-qter. 
RKO 2 2 4 +7q32–34, +8q21.1-qter, –2q37 & –6p23-pter 
HT29 5 4 9 ++8q22-qter, +11, +12q24.1-qter, +13q12.2, +20q, 
–3p12.3–13, –8p21-pter, –18q & –21q 
DLD1 2 2 4 +1p35-pter, +9q34-qter, –13q31 & –18 
CACO2 6 3 9 +10q21-pter, +11q13-qter, +12p, +16q23-qter, +17q 
+20q, –1p, –9p22-pter & –18q 
BE 3 4 7 +14q22-qter, +19q ++20q, –8q21.2-pter, –9p21-pter, 
–10p15 & –18q21-qter 
LOVO 1 0 1 +12q24.1-pter 1494 PH Rooney et al 
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Almost every chromosomal arm was detected as changed in at
least 1 of the 37 cancer genomes assessed (Figures 1 and 2). 
Genome-wide analysis of some tumours (i.e., tumours 4, 12, 13,
18, 22, 24) detected no changes, while other cases showed multiple
aberrations (e.g., tumours 15 and 28 showed a total of 17 and 20
chromosomal aberrations, respectively) (Table 2). The median
number of gains per tumour was 2.0 (mean 3.7, 108 gains/29
tumours), while the median loss was 1.0 aberration per tumour
(mean 2.9, 85 losses/29 tumours). The median genetic grade was
4.0 (mean 6.7, 193 aberrations/29 tumours). For tumours the
genetic grade was not normally distributed, with the suggestion of
a multimodal distribution (Figure 4). The chromosomal regions
most frequently gained in the 29 tumours globally assessed by
CGH were 13q (27.6%), 20q (27.6%), 7p (24.1%), 8q (24.1%) and
1q (20.7%) (Table 2; Figure 3). The most frequent losses of chro-
mosomal material in the tumours occurred at 18q (31%), 4q
(20.7%), 17p (20.7%), 18p (20.7%) and 15q (20.1%) (Table 2;
Figure 3). High level amplification (FR > 1.5) was seen in two
Table 2 Chromosomal aberrations detected by CGH in 29 Dukes’ C colo-rectal tumours 
Tumour Status Follow-up CGH aberrations 
no. (alive [1] (months) (+ = Gain, – = Loss and ++ = High level amplification) 
dead [0])
1 1 54 +8p22–23, +8q22–24.2, +11p15, +20p, –2q21, –4q34–35, –6p, 
–6q, –9cent-q13, –10p, –10q, –12cent-q13, –13q21 & –14q32.3 
2 0 28 +5p21, +6p25, +7p, +7q, +10p15, +20p12, +20q12-qter, 
–1q12, –9q12–21, –12q24.1-qter, –13q21.2-qter, –16p11.2- 
16q11.2, –18cent-p11.2, –19p & –19q 
3 0 14 +8q22-qter 
4 1 49 none detected 
51 2 9 –2p, –2q, –8p12–21, –10q22-qter, –15q22 & –18q21–23 
6 1 25 +1q31–32, +3p26.1, +8q, +13q, +20p, +20q & –1p36.1, 
–3p22-qter, –4p, –9p, –16p13.2–13.3, –18p, –18q & –22q13 
7 1 24 +1p33–1q21 & –9p24-q21 
808 –3p25–26 
9 1 23 +1p12–q31, +1q12–22, +2p12–12, +5p, +7p, +13q32, 
+14q12–13, –3cent-q21, –4p12–14, –14q32, –17p13, –17q11.2, 
& –18p11.3 
10 1 23 +1q12–21,+8q, +9q12–21,+20p, +20q, –2q23, –4q22–24, 
–5q15–31,–6q16-qter, –8p & –18q12–22 
11 1 35 +1q12, +5cent, +13q, +16p11.2-q21.2, +16p13.3, +20q, –1q, 
–2p, –7p13–21, –9p12, –15q13–21, –18q12 & –21q22 
12 1 28 none detected 
13 0 19 none detected 
14 1 38 +1p12–21,+7p, +7q, +13q, +16p, +16q, ++20q, –1p13–31, 
–3q11.2–13.1,–5q13–23, –8p23, –17p, –18p, –18q, –21q22 
15 1 28 +2p16, +2q21–24, +4p12–14, +4p15, 4q22, +7p13–15, +7q31, 
+8q23–24.1,+9p22, +13q, +14p15, +16p13.1-qter, +16q23- 
qter, –1q12, –4p16, –8p21–22, –17p, –17q & –19p 
16 1 50 –9p22–24 
17 1 43 +6p25, +17q22–24, –4q21–22 & –11p13–14 
18 1 46 none detected 
19 1 22 +8q22–24.1,+12p13, +13q, +20q, –7q22–31, –14q, –15q24- 
25, –17p11.2, –18p, –18q & –20p 
20 0 13 –15q & –17p12–13 
21 1 45 +3q23–25, +5q14–21, +17p13, +20q13.2–13.3, & –14q23–24 
22 1 29 none detected 
23 1 29 +2q24–32, +7p, +12p, +12q, +13q, +20p, +20q, –4q27-qter, 
–6q21-qter, –11q13-qter, –18p, –18q & –21q 
24 0 7 none detected 
25 0 12 –19q13.2–13.4 
26 1 47 +9q12–21.2, –19p13.2 & –21q22 
27 0 43 +7p21–22, +7q21, +9p24, +17p13, –2q, –4q33–34, –11p14–15 
& –15q13–14 
28 1 29 +2p, +3p22, +7p, +7q, +11q23, ++13q, +19q12–q13.1,+20p, 
–1p, –4p, –4q, –5p, –5q, –10p, –10q, –12p, –12q, –15q24–q25, 
–17p & –18q 
29 0 6 –16q24 & –18q12–22 Colo-rectal cancer genomics 1495
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tumours; tumour 14 on 20q (whole arm) and tumour 28 on 13q
(whole arm). 
In the cell lines gain of chromosomal material was slightly more
common than loss (mean 4.5 gains, 36 gains/8 cell lines; mean 3.4
losses, 27 losses/8 cell lines). The median number of gains per cell
line was 4.0 while the median number of losses was 3.5. The
median genetic grade was 8.0 (mean 7.8, 63 aberrations/8 cell
lines). 20q was the most common region of gain, being detected in
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Figure 1 Summary of regions of genomic change in tumour DNA from 29 Dukes’ C colorectal tumours detected by CGH. Bars on the left side of the
chromosome ideogram denote a loss, bars on the right side a gain of sequence in the tumour genome. Regions of high-level copy number increases
(amplifications) are indicated by solid/bold bars 
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Figure 2 Summary of regions of genomic change in DNA from 8 colo-rectal cancer cell lines detected by CGH. Bars on the left side of the chromosome
ideogram denote a loss, bars on the right side a gain of sequence in the tumour genome. No regions of high-level copy number increases (amplifications) were
detected 1496 PH Rooney et al 
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62.5% (5/8 cell lines) of all the cell lines assessed. Other common
regions of gain included; 11q and 13q which were both gained in
37.5% or 3/8 of cell lines. Considering the chromosomal arms
most commonly lost across the cell lines, 18q showed the highest
level of aberration being detected in 75% of the cell lines (6/8). 1q
was the second most commonly lost region, found changed in
37.5% of the cell lines (3/8). All cell lines contained at least one
aberration detectable by CGH. 
The 5 most common regions of gain (13q, 20q, 7p, 8q, 20p) and
the 5 most common losses (18q, 4q, 15q, 17p, 18p) in the 29 CRC
tumours were evaluated for influences on patient survival. No
association between any specific chromosomal aberration and
patient survival was demonstrated (P > 0.05 for all analysis).
However, the level of chromosomal aberration detected per
tumour (the genetic grade) was found to be associated with
survival. Patients with tumours containing > 2 aberrations had a
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better survival than those with tumours containing ≤ 2 aberrations
(P = 0.02, Figure 5). 95% of patients with > 2 aberrations (16/17)
were alive at 22 months (the minimum follow-up for all
patients) compared to 42% of patients with tumours displaying ≤ 2
aberrations (5/12). The median survival was 14 months in patients
with ≤ 2 aberrations, where as median survival was not yet reached
in the patients with > 2 aberrations per tumour. 
DISCUSSION 
In this analysis of Dukes’ C CRC, a significant difference in
survival was observed between tumours which had > 2 aberrations
and those which had ≤ 2 aberrations. In contrast, analysis of the
top five gains and losses detected by CGH found no association
between specific chromosomal aberrations and survival. This data
suggests that the overall genomic context of the tumour, rather
than the specific aberrant loci, is of clinical relevance in CRC.
While this varies from the traditional dogma that specific genes
(e.g., angiogenic proteins, metalloproteinases, antiapoptotic genes,
therapeutic targets) are mediating the outcome of advanced cancer,
the current findings are in line with the recent emphasis on genomic
instability as a key event in tumour cells (Cahill et al, 1999). The
mechanistic basis for altered genetic grade in CRC is not clear, but
mutations in several candidate pathways (e.g., mitotic spindle
checkpoint) have been identified (Cahill et al, 1998).
To date, no other study of CRC has attempted to associate
tumour chromosomal stability/genetic grade with survival, as
detected by CGH. However, a recent study investigating a less
common mechanism for a mutator phenotype, microsatellite insta-
bility (MIN), also detected an association between genetic stability
and survival (Gryfe et al, 2000). Analysis of clinical outcome in
both unselected CRC patients and those ≤ 50 years of age found
that MIN was independently predictive of a favourable outcome.
Why increased genetic instability, whether it manifests itself
as MIN (Gryfe et al, 2000) or increased chromosomal aberration
(as detected here), should be associated with a favourable outcome
is not known. It has been suggested that a tumour can have an
excess of genomic instability, spurring the tumour cells into
various mechanisms of cell death (Cahill et al, 1998). 
CGH analysis identified several regions of the genome associ-
ated with tumourigenesis in the Dukes’ C colorectal tumours. The
general trend of genomic instability detected in the carcinomas
assessed in this study mirrors that identified by CGH in other
colorectal carcinomas (Rooney et al, 1999). Although the trend of
loss and gain is similar, there is variation between the observed
frequency of specific altered regions between the current study
and the pooled data from previous reports. For example, gain of
chromosome 13q was detected in 27.6% of carcinomas in this
study, but in 50% in other studies of colorectal carcinoma by
CGH (Reid et al, 1996; De Angelis et al, 1999; Georgiades et al,
1999). This could reflect the focus on a single disease stage
(Dukes’ C). However, there is a more likely technical explanation
for these differences. In this study, only aberrations detected in
both the forward and reverse CGH reaction were used in the
analysis. The addition of a fluorochrome reversal step to conven-
tional CGH reduces the risk of false positives, a potential problem
with many currently used CGH protocols (Barth et al, 2000). It
also allows the sub-chromosomal regions identified as altered by
CGH to be more precisely defined by using two profiles to define
a region of change rather than one. If the approach used in this
study is more thorough, then this data suggests that the CGH liter-
ature may be over-estimating the level of genetic aberrations in
CRC tumours. 
The genetic grade for the Dukes’ C CRC was not unimodal
(Figure 4). Six tumours (21%) had no aberrations detected, 12
(41%) had between 1 and 8 aberrations detected per genome
assessed, while the other group of tumours had between 11 and 20
(38%) aberrations per tumour. A similar distribution was recently
observed in a study of CRC using CGH (De Angelis et al, 1999).
This multimodal distribution of chromosomal aberrations across
CRC tumours is consistent with the hypothesis that multiple pheno-
types exist for CRC (Georgiades et al, 1999; Hawkins et al, 2001). 
The value of cell lines to further study of genetic aberrations
observed by CGH analysis has already been demonstrated in breast
cancer. In this tumour type initial detection of a region of amplifi-
cation on chromosome arm 20q followed by high density fluores-
cence in situ hybridization mapping experiments in breast cancer
cell lines helped isolate several putative oncogenes within the
amplicon (Kallionemi et al, 1994; Collins et al, 1998). Adapting a
similar approach to the study of genomic aberrations associated
with CRC should speed the identification of the crucial genes
driving the CGH signature. There is concern about the relevance of
in vitro model systems, as previous studies have demonstrated that
continuous culture of tumour cell lines allows, and possibly encour-
ages, random genomic aberrations (Reiss et al, 1986; Jones et al,
2000). Comparing the CGH data for the 29 solid tumours and 8 cell
lines in this study found that the regions of alteration were similar
in both systems. Furthermore, the most common aberrations were
often the same for both systems. For example, 18q loss and 20q
gain were the most common region of loss and gain in both the
tumours and the cell lines. However, the actual frequency of the
aberrations was higher in the cell lines. For example, 20q gain was
detected in 27.6% of the tumours and 62.5% of the cell lines, while
18q was detected as lost in 31% of tumours and 75% of cell lines.
The median number of total aberrations per cell line was 8
compared to a median of 4 for the colorectal tumours. Furthermore,
21% of CRC had no aberrations, while 100% of cell lines had at
least one region of loss or gain. These results support the recent
hypothesis that some colorectal genotypes (particularly diploid
tumours) could be absent in currently available cell culture models
(Hawkins et al, 2001). The mechanistic basis for the observed bias
in genome aberration frequency is not yet defined. 
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The results of this study suggest that above a certain threshold of
genomic instability (e.g., > 2 aberrations), an unstable genome confers
a survival advantage in CRC. Whether this threshold associated with
survival is directly related to tumour aggression or is specifically
conferring resistance to therapies, such as chemotherapy, is not
known. In addition, the chromosomal aberrations detected by CGH
analysis of colo-rectal solid tumours and colo-rectal cell lines were
present in both systems, but the frequency of aberrations was
greater in the cell lines. This suggests that many cell lines would be
appropriate models for the subset of tumours with high frequency
chromosomal changes, but careful evaluation is required to identify
those representative of most Dukes’ C CRC. 
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